SNES vs PAHC vs NEOG vs CTVA

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). Phibro Animal Health Corporation (PAHC) offers the better valuation at 36. 3x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Phibro Animal Health Corporation (PAHC) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Phibro Animal Health Corporation (PAHC) is the cheapest at 36.

3x versus Corteva, Inc. at 49. 4x. On forward P/E, Phibro Animal Health Corporation is actually cheaper at 14. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Corteva, Inc. wins at 1. 81x versus Phibro Animal Health Corporation's 1. 90x — a reasonable growth-adjusted valuation.

Over the past 5 years, Corteva, Inc.

(CTVA) delivered a total return of +68. 3%, compared to -99. 9% for SenesTech, Inc. (SNES). Over 10 years, the gap is even starker: CTVA returned +186. 7% versus SNES's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Corteva, Inc.

(CTVA) is the lower-risk stock at 0. 29β versus Neogen Corporation's 1. 83β — meaning NEOG is approximately 523% more volatile than CTVA relative to the S&P 500. On balance sheet safety, Corteva, Inc. (CTVA) carries a lower debt/equity ratio of 11% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, SNES leads at 29. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Corteva, Inc.

(CTVA) is the more profitable company, earning 6. 3% net margin versus -287. 4% for SenesTech, Inc. — meaning it keeps 6. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTVA leads at 15. 1% versus -292. 9% for SNES. At the gross margin level — before operating expenses — SNES leads at 62. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Corteva, Inc. (CTVA) is the more undervalued stock at a PEG of 1. 81x versus Phibro Animal Health Corporation's 1. 90x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Phibro Animal Health Corporation (PAHC) trades at 14. 2x forward P/E versus 25. 9x for Neogen Corporation — 11. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NEOG: 18. 9% to $11. 00.

In this comparison, PAHC (1.

1% yield), CTVA (0. 9% yield) pay a dividend. SNES, NEOG do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Corteva, Inc.

(CTVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 9% yield, +186. 7% 10Y return). Neogen Corporation (NEOG) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CTVA: +186. 7%, NEOG: -49. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SNES (Basic Materials) and PAHC (Healthcare) and NEOG (Healthcare) and CTVA (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SNES is a small-cap high-growth stock; PAHC is a small-cap high-growth stock; NEOG is a small-cap quality compounder stock; CTVA is a mid-cap quality compounder stock. PAHC, CTVA pay a dividend while SNES, NEOG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.